TAR-200 monotherapy demonstrates highest CRR reported to date with sustained clinical benefits in patients with certain types of bladder cancer April 30, 2025
OLYMPUS Long-Term Follow-Up shows Nearly 4-Year DoR in Patients with LG-UT Urothelial Cancer Who Achieved a Complete Response to prior JELMYTO Treatment April 30, 2025
Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec announced April 30, 2025
TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Ph 2b SunRISe-1 study (Cohort 2) in NMIBC patients April 22, 2025
Supplemental BLA submitted to FDA for use of ANKTIVA® plus BCG in BCG-unresponsive NMIBC for the indication of papillary disease April 22, 2025
FDA approves Pluvicto for earlier use before chemotherapy in PSMA-positive metastatic CRPC April 2, 2025
Relmada Therapeutics Licenses Ph 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma April 2, 2025
75.5% CR at any time in Ph 3 study of cretostimogene monotherapy for high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS) April 2, 2025
Imfinzi approved in the US as perioperative immunotherapy for patients with muscle-invasive bladder cancer April 2, 2025
FRUSICA-2 Ph 2/3 Study of Sintilimab and Fruquintinib Combination Met Primary Endpoint in Advanced RCC in China March 26, 2025
EMA approves WELIREG® (belzutifan) for advanced clear cell RCC that progressed following a PD(L)-1 inhibitor and at least two VEGF therapies February 25, 2025
US FDA grants Fast Track Designation to Cu-67 SAR-bisPSMA for the treatment of metastatic CRPC patients February 25, 2025
ASCO GU 2025: PADCEV + KEYTRUDA Show Long-Term Efficacy in 1L Treatment of Locally Advanced or Metastatic Urothelial Cancer February 19, 2025
IMFINZI perioperative regimen improved EFS and OS across MIBC patients regardless of cPR status in post-hoc exploratory analysis of NIAGARA Ph 3 trial February 19, 2025
Data from Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median DOR of ~4 Years in Patients Achieving CR with JELMYTO Published in The Journal of Urology February 19, 2025
ASCO GU 2025: Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX + Opdivo in Patients with Advanced Kidney Cancer Announced February 19, 2025
ASCO GU 2025: New Data reported for Casdatifan in Patients with Metastatic Kidney Cancer February 19, 2025
ASCO GU 2025: New data for darolutamide confirm safety and improved efficacy across subgroups of patients with mHSPC February 19, 2025
